American journal of clinical dermatology

Lebrikizumab Maintains 48-Week Efficacy in Systemic-Naive and Experienced Atopic Dermatitis

A prospective study of 187 patients shows high response rates, though prior systemic therapy may limit clearance in head and neck lesions.